Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat…
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
AI in Healthcare and Digital Health Today—March 16, 2026
This week’s AI in Healthcare and Digital Health update highlights…
Lucid Diligence Brief: China approves Boruik Kang (Neuracle) invasive BCI implant for paralysis
Lucid Diligence Brief: China approves Boruik Kang (Neuracle) invasive BCI…
Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835 million
Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835…
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…
Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million
Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million…
AI in Healthcare and Digital Health Video Recap—March 11, 2026
This biweekly AI in Healthcare and Digital Health video recap highlights safety…
Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge
Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge…
Lucid Diligence Brief: kyron.bio x Servier strategic partnership
Lucid Diligence Brief: kyron.bio x Servier strategic partnership Professional…


